Opinion

Video

Final Thoughts on Retinal Disease Treatments and Outcomes

Author(s):

Ehsan Rahimy, MD,Jonathan Jonisch, MD

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
Related Content
Gildeuretinol Shows Promise in Slowing Geographic Atrophy Progression | Image Credit: The Retina Group of Washington
October 21st 2024

Gildeuretinol Shows Promise in Slowing Geographic Atrophy Progression

Connor Iapoce
New Insight: A Look at Corneal Transplant Alternatives w/ John Sheets, PhD | Image Credit: HCPLive
September 5th 2024

New Insight: A Look at Corneal Transplant Alternatives w/ John Sheets, PhD

Connor Iapoce
Face Masking Did Not Affect Endophthalmitis Rates After Anti-VEGF Injections | Image Credit: Wills Eye Hospital
October 21st 2024

Face Masking Did Not Affect Endophthalmitis Rates After Anti-VEGF Injections

Connor Iapoce
MEDcast logo
August 1st 2024

Optimizing Treatment Outcomes in Retinal Vein Occlusion

Hong-Uyen Hua, MD Sruthi Arepalli, MD Geeta Lalwani, MD
SKYLINE: AGTC-501 Shows Positive 24-Month Data in X-Linked Retinitis Pigmentosa| Image Credit: V2osk/Unsplash
October 19th 2024

SKYLINE: AGTC-501 Reports Positive 24-Month Data in X-Linked Retinitis Pigmentosa

Connor Iapoce
ARCHER: ANX007 Mitigates Visual Acuity Loss in Geographic Atrophy| Image Credit: ASRS
October 19th 2024

ARCHER: ANX007 Mitigates Visual Acuity Loss in Geographic Atrophy

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.